FindTrial
Sign In

Phase 3 Clinical Study of TA-4708 (Bisoprolol Fumarate) in Patients with Chronic Heart Failure.

Phase 3 Clinical Study of TA-4708 (Bisoprolol Fumarate) in Patients with Chronic Heart Failure.

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221012
Enrollment
Unknown
Registered
2010-02-25
Start date
2010-02-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic heart failure

Interventions

investigational material(s) Generic name etc : TA-4708 (Bisoprolol Fumarate) INN of investigational material : Therapeutic category code : 219 Other cardiovascular agents Dosage and Administration fo

Sponsors

Tanabe Pharma Corporation
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: > Stable symptoms of chronic heart failure Severity: (1) NYHA functional class: IIM or III (2) LVEF: =Others Basic treatment for heart failure: Treatment with an ACE inhibitor or ARB and a diuretic, etc.

Exclusion criteria

Exclusion criteria: > Hypertrophic obstructive cardiomyopathy > Progressive myocarditis > Valve stenosis as the main aetiology or serious valve regurgitation, etc.

Design outcomes

Primary

MeasureTime frame
Efficacy (heart function tests, etc.) Safety (death or hospitalization, etc.)—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026